Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Puig

Showing results (31-40 of 423) with videos related to

Pageof 43
Sort By:
Business and Health|October 6, 1989
Health care comes home for savingsL Puig
The British Journal of Dermatology|October 30, 2016
Interleukin-17 in skin: psoriasis and yonderL Puig
Actas Dermo-Sifiliograficas|January 1, 2008
[Which patient is a candidate for treatment with efalizumab and why?]L Puig
Drugs of Today (Barcelona, Spain : 1998)|June 27, 2017
Brodalumab: the first anti-IL-17 receptor agent for psoriasisL Puig
Actas Dermo-Sifiliograficas|December 17, 2008
[Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients]L Puig
Actas Dermo-Sifiliograficas|January 30, 2010
[Biosimilars or follow-on biologics in dermatology]L Puig
Actas Dermo-Sifiliograficas|September 11, 2012
Response to: "On Cardiovascular Risk Estimation in Patients With Psoriasis: The REGICOR and SCORE Scales"L Puig
Journal of the European Academy of Dermatology and Venereology : JEADV|July 5, 2012
Treatment of severe psoriasisL Puig
Medicina Clinica|April 20, 1985
[Bases and current indications for plasma exchange]L Puig Rovira
Actas Dermo-Sifiliograficas|August 1, 2007
[Psoriasis, a systemic disease?]L Puig-Sanz
Pageof 43

Showing results (31-40 of 423) with videos related to

Sort By:
Pageof 43
Business and Health|October 6, 1989
Health care comes home for savingsL Puig
The British Journal of Dermatology|October 30, 2016
Interleukin-17 in skin: psoriasis and yonderL Puig
Actas Dermo-Sifiliograficas|January 1, 2008
[Which patient is a candidate for treatment with efalizumab and why?]L Puig
Drugs of Today (Barcelona, Spain : 1998)|June 27, 2017
Brodalumab: the first anti-IL-17 receptor agent for psoriasisL Puig
Actas Dermo-Sifiliograficas|December 17, 2008
[Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients]L Puig
Actas Dermo-Sifiliograficas|January 30, 2010
[Biosimilars or follow-on biologics in dermatology]L Puig
Actas Dermo-Sifiliograficas|September 11, 2012
Response to: "On Cardiovascular Risk Estimation in Patients With Psoriasis: The REGICOR and SCORE Scales"L Puig
Journal of the European Academy of Dermatology and Venereology : JEADV|July 5, 2012
Treatment of severe psoriasisL Puig
Medicina Clinica|April 20, 1985
[Bases and current indications for plasma exchange]L Puig Rovira
Actas Dermo-Sifiliograficas|August 1, 2007
[Psoriasis, a systemic disease?]L Puig-Sanz
Pageof 43